양극성장애에서 Antipsychotics의 사용 전략
Strategies of Using Antipsychotics in Patients with Bipolar Disorders
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bipolar disorder is a recurrent chronic condition and patients usually continue long-term medication from young age to prevent the recurrence of mood episodes. Antipsychotics play an important role in acute and maintenance treatment of bipolar disorder, even when patients experience no psychotic symptoms. Antipsychotics are also used in monotherapy and combination therapy involving mood stabilizers such as lithium or valproate. However, limited antipsychotics are currently approved by the US Food & Drug Administration ; 10 kinds of antipsychotics were approved for manic or mixed episodes, 3 for bipolar depression, and 5 for maintenance therapy. Before and after the use of antipsychotics, psychiatrists should carefully monitor baseline weight, pulse, blood pressure, fasting blood glucose or HbA1c, blood lipid profile, and electrocardiogram to evaluate QTc prolongation. During manic episodes or mixed features, antipsychotics rapidly control agitation, aggression, and impulsivity. Repetitive injections of typical antipsychotics are not implemented in bipolar patients as this practice is not evidence-based. However, long-acting injectable atypical antipsychotics are approved and feature support on maintenance therapy for bipolar patients. Although recent studies have shown the benefits of aripiprazole and olanzapine on rapid-cycling bipolar patients, few studies support the effectiveness of antipsychotics in suicide prevention. Moreover, while there is extensive evidence on the effectiveness of lithium in suicide or self-harm prevention. In conclusion, antipsychotics, especially aripiprazole, quetiapine, olanzapine, and risperidone, are effective to manage bipolar disorder in clinical settings. But weight gain and cardiac conductance should be carefully monitored before and during the use of antipsychotics.
Abstract
Bipolar disorder is a recurrent chronic condition and patients usually continue long-term medication from young age to prevent the recurrence of mood episodes. Antipsychotics play an important role in acute and maintenance treatment of bipolar disorder, even when patients experience no psychotic symptoms. Antipsychotics are also used in monotherapy and combination therapy involving mood stabilizers such as lithium or valproate. However, limited antipsychotics are currently approved by the US Food & Drug Administration ; 10 kinds of antipsychotics were approved for manic or mixed episodes, 3 for bipolar depression, and 5 for maintenance therapy. Before and after the use of antipsychotics, psychiatrists should carefully monitor baseline weight, pulse, blood pressure, fasting blood glucose or HbA1c, blood lipid profile, and electrocardiogram to evaluate QTc prolongation. During manic episodes or mixed features, antipsychotics rapidly control agitation, aggression, and impulsivity. Repetitive injections of typical antipsychotics are not implemented in bipolar patients as this practice is not evidence-based. However, long-acting injectable atypical antipsychotics are approved and feature support on maintenance therapy for bipolar patients. Although recent studies have shown the benefits of aripiprazole and olanzapine on rapid-cycling bipolar patients, few studies support the effectiveness of antipsychotics in suicide prevention. Moreover, while there is extensive evidence on the effectiveness of lithium in suicide or self-harm prevention. In conclusion, antipsychotics, especially aripiprazole, quetiapine, olanzapine, and risperidone, are effective to manage bipolar disorder in clinical settings. But weight gain and cardiac conductance should be carefully monitored before and during the use of antipsychotics.
참고문헌 (47)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (2013), American Psychiatric Association Publishing
- clinical psychiatry, "Kaplan and Sadock’s synopsis of psychiatry:behavioral sciences", pp.2014, Sadock BJ
- Solomon DA, "Longitudinal course of bipolar I disorder : duration of mood episodes", Arch Gen Psychiatry, 67, pp.339~347 (2010)
- Judd LL, "The long-term natural history of the weekly symptomatic status of bipolar I disorder", Arch Gen Psychiatry, 59, pp.530~537 (2002)
- Judd LL, "A prospective investigation of the natural history of the longterm weekly symptomatic status of bipolar II disorder", Arch Gen Psychiatry, 60, pp.261~269 (2003)
- Schaffer A, "Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder:part I of a report of the international society for bipolar disorders task force on suicide in bipolar disorder", Aust N Z J Psychiatry, 49, pp.785~802 (2015)
- Morton E, "Quality of life in bipolar disorder : towards a dynamic understanding", Psychol Med, 48, pp.1111~1118 (2018)
- Cipriani A, "Comparative efficacy and acceptability of antimanic drugs in acute mania : a multiple-treatments meta-analysis", Lancet, 378, pp.1306~1315 (2011)
- Cipriani A, "Olanzapine in the long-term treatment of bipolar disorder : a systematic review and meta-analysis", J Psychopharmacol, 24, pp.1729~1738 (2010)
- Vieta E, "Bipolar disorders", Nat Rev Dis Primers, 4, pp.18008~ (2018)
- "Accessdata.fda.gov" (2018)[URL]
- National Institute for Health and Care Excellence (NICE)., "NICE guidelines:using pharmacological treatments for bipolar disorder" (2018), NICE Publishing
- Zarate CA Jr., "Antipsychotic drug side effect issues in bipolar manic patients", J Clin Psychiatry, 61(Suppl 8), pp.52~61 (2000)
- Nierenberg AA, "A critical appraisal of treatments for bipolar disorder", Prim Care Companion J Clin Psychiatry, 12(Suppl 1), pp.23~29 (2010)
- Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
- Altınbaş K, "Clinical potential of cariprazine in the treatment of acute mania", Psychiatr Danub, 25, pp.207~213 (2013)
- Li DJ, "Efficacy, safety and tolerability of aripiprazole in bipolar disorder: an updated systematic review and meta-analysis of randomized controlled trials", Prog Neuropsychopharmacol Biol Psychiatry, 79, pp.289~301 (2017)
- Scheidemantel T, "Asenapine for bipolar disorder", Neuropsychiatr Dis Treat, 11, pp.3007~3017 (2015)
- Lao KS, "Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with metaanalysis of randomized controlled trials", CNS Drugs, 30, pp.1043~1054 (2016)
- Gurovich I, "QTc prolongation : chlorpromazine and high-dosage olanzapine", Can J Psychiatry, 48, pp.348~ (2003)
- Kane JM, "Lurasidone : a clinical overview", J Clin Psychiatry, 72(Suppl 1), pp.24~28 (2011)
- Silva MT, "Olanzapine plus fluoxetine for bipolar disorder : a systematic review and meta-analysis", J Affect Disord, 146, pp.310~318 (2013)
- Endicott J, "Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder : improvements in quality of life and quality of sleep", J Affect Disord, 111, pp.306~319 (2008)
- Chiesa A, "Quetiapine for bipolar depression : a systematic review and meta-analysis", Int Clin Psychopharmacol, 27, pp.76~90 (2012)
- Samalin L, "Quetiapine extended release for the treatment of bipolar disorder", Expert Rev Neurother, 14, pp.987~1005 (2014)
- Kim SJ, "Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression", J Affect Disord, 157, pp.33~40 (2014)
- Sheehan DV, "Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient", J Affect Disord, 145, pp.83~94 (2013)
- Fenton C, "Risperidone : a review of its use in the treatment of bipolar mania", CNS Drugs, 19, pp.429~444 (2005)
- Bobo WV, "Risperidone long-acting injectable(Risperdal Consta®)for maintenance treatment in patients with bipolar disorder", Expert Rev Neurother, 10, pp.1637~1658 (2010)
- Coughtrie AL, "Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort", BMJ Open, 7, pp.e016627~ (2017)
- Nielsen J, "Assessing QT interval prolongation and its associated risks with antipsychotics", CNS Drugs, 25, pp.473~490 (2011)
- American Psychiatric Association Steering Committee on Practice Guidelines, "Treating bipolar disorder a quick reference guide" (2005), American Psychiatric Association Publishing
- Chouinard G, "A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms", Can J Psychiatry, 38(Suppl 4), pp.S114~S121 (1993)
- Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
- Bartoli F, "Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression : a meta-analysis", J Psychiatr Res, 88, pp.38~46 (2017)
- Lindström L, "Maintenance therapy with second generation antipsychotics for bipolar disorder-A systematic review and meta-analysis", J Affect Disord, 213, pp.138~150 (2017)
- Calabrese JR, "Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study", J Clin Psychiatry, 78, pp.324~331 (2017)
- Quiroz JA, "Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder", Biol Psychiatry, 68, pp.156~162 (2010)
- Tohen M, "Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression", Arch Gen Psychiatry, 60, pp.1079~1088 (2003)
- Kelly T, "The utility of low-dose aripiprazole for the treatment of bipolar II and bipolar NOS depression", J Clin Psychopharmacol, 37, pp.99~101 (2017)
- Yatham LN, "A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder", J Affect Disord, 128(Suppl 1), pp.S21~S28 (2011)
- Schneck CD, "Treatment of rapid-cycling bipolar disorder", J Clin Psychiatry, 67(Suppl 11), pp.22~27 (2006)
- Fountoulakis KN, "A systematic review of the evidence on the treatment of rapid cycling bipolar disorder", Bipolar Disord, 15, pp.115~137 (2013)
- Smith KA, "Lithium and suicide in mood disorders : updated meta-review of the scientific literature", Bipolar Disord, 19, pp.575~586 (2017)
- Cipriani A, "Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders : a systematic review of randomized trials", Am J Psychiatry, 162, pp.1805~1819 (2005)
- Hayes JF, "Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study", JAMA Psychiatry, 73, pp.630~637 (2016)
- Ballard ED, "Acute risk factors for suicide attempts and death : prospective findings from the STEP-BD study", Bipolar Disord, 18, pp.363~372 (2016)